Erik T Goluboff, MD
- PROFESSOR | Urology
Research Topics:Anti-Tumor Therapy, Cancer, Kidney, Prostate
Dr. Erik Goluboff is an Attending Physician in the Department of Urology at Mount Sinai Beth Israel Medical Center and Professor of Urology at Icahn School of Medicine at Mount Sinai. He earned an MBA at NYU's Stern School of Business, with specializations in corporate finance, financial instruments, and management. Previously, he was Director of Urology at New York-Presbyterian Hospital/The Allen Pavilion and a Professor of Clinical Urology at Columbia University College of Physicians and Surgeons. Dr. Goluboff is a board certified urologist and a Magna Cum Laude, Phi Beta Kappa graduate of Columbia College of Columbia University and an Alpha Omega Alpha graduate of the Johns Hopkins University School of Medicine. He completed a year of general surgical residency at Johns Hopkins, followed by surgery and urology residency training at Columbia. He also completed a urologic oncology fellowship at Columbia, sponsored by a Ferdinand C. Valentine Fellowship from the New York Academy of Medicine and a Young Investigator Award from the American Society of Clinical Oncology. During this fellowship, he had additional training in the diagnosis and surgical treatment of urologic cancers such as prostate, bladder, kidney, penis and testis.Dr Goluboff is a fellow of the American College of Surgeons.
Dr. Goluboff has won many awards during almost two decades in urology, including the Young Investigator Award from the National Kidney Foundation, First Prize Laboratory Investigation-Valentine Essay Contest New York Academy of Medicine, Honorable Mention- Valentine Essay Contest New York Academy of Medicine, and a Pfizer Scholar in Urology Award (twice). He has performed over 3000 surgeries including over 1000 radical prostatectomies for prostate cancer, either by the open or robotic approaches. Dr. Goluboff has authored over 150 papers (of which a few are listed below) and participated in many clinical trials for new drugs for urologic disorders.
Dr. Goluboff is dedicated to the rational, efficient, and compassionate care of patients with urologic disease.
For more information please visit Dr. Goluboff's LinkedIn page and/or follow him on Twitter.
American Board of Urology
- Benign Prostatic Hyperplasia
- Bladder Cancer
- Frequent Urination
- Kidney Cancer
- Lower urinary tract symptoms
- Orchitis / Epididymitis
- Penile Cancer
- Prostate Biopsy
- Prostate Cancer
- Prostate Cancer Screening
- Prostate-Specific Antigen (PSA) Test
- Radical Cystectomy
- Renal Mass
- Testicular Cancer
- Urology Second Opinion
MD, Johns Hopkins School of Medicine
MBA, New York University Stern School of Business
Internship, Surgery, Johns Hopkins School of Medicine
Residency, Surgery, NY Columbia Presbyterian Med. Ctr.
Residency, Urology, NY Columbia Presbyterian Med. Ctr.
Fellowship, Urology Oncology, NY Columbia Presbyterian Med. Ctr.
Executive MBA Class Valedictorian
America's Top Surgeons
Compassionate Doctor Award
Patient's Choice Award
America's Top Urologists
Top Doctors New York Metro Area
Dr. Goluboff's primary areas of study are urologic cancer, kidney disease, advanced cancer and prostate health. His research focuses on outcomes from urologic oncologic surgical procedures; maximizing the cost/benefit ratio of treatments; and the increasing understanding of new mechanisms of action for treatments, drugs, and devices for improving outcomes for patients with prostate, bladder, kidney, and testis cancers.
Sprenkle P, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Nenson M, Rutman M. Exploring medical student education initiatives: Does the management of urologic conditions improve with a formal urology clinical clerkship. Journal of Medicine and the Person 2011;(9): 116-122.
Zyflamend in men with high-grade prostate intraepithelial neoplaisa. Results of PHASE 1 CLINICAL TRIAL.. JSIO 2009;.
Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007 Oct; 70(4).
Pierorazio PM, Kinnaman MD, Wosnitzer MS, Benson MC, McKiernan JM, Goluboff ET. Prostate volume and pathologic prostate cancer outcomes after radical prostatectomy. Urology 2007 Oct; 70(4).
Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives. Urology 2007 Mar; 69(3).